Chu Reims
Reims, 51092, France
NCT Number: NCT03319693
Primary mucosal melanomas (MPM) are rarer than cutaneous melanomas, but also more severe. They are usually refractory to conventional approaches, regularly excluded from major therapeutic programs and not sensitive to new targeted therapies orphans. " The identification of therapeutic targets and accessibility to existing, developing or future targeted therapies improves the survival of patients with MPM.
The principal goal is to describe, using a large panel of genes, the prevalence of major mutations in a cohort of MPMs based on the population of a French region.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Reims, 51092, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
NGS analysis
Time frame: Day 0
NGS panel
CHU de Reims
Other
Acronym: MELMUQ
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01989572
Eye Diseases, Eye Neoplasms
Birmingham, Alabama, United States
View Trial DetailsNCT05628883
Acral Melanoma, Conjunctival Melanoma
Tampa, Florida, United States
View Trial DetailsNCT07506447
FDG PET, Mucosal Melanoma
Wuhan, Hubei, China
View Trial DetailsNCT02858869
Brain Diseases, Brain Neoplasms
Atlanta, Georgia, United States
View Trial Details